DME Capital Management LP Raises Stock Holdings in Coya Therapeutics, Inc. (NASDAQ:COYA)

DME Capital Management LP lifted its holdings in Coya Therapeutics, Inc. (NASDAQ:COYA) by 29.2% in the fourth quarter, HoldingsChannel reports. The firm owned 1,646,440 shares of the company’s stock after purchasing an additional 372,414 shares during the quarter. Coya Therapeutics accounts for 0.5% of DME Capital Management LP’s portfolio, making the stock its 23rd largest position. DME Capital Management LP owned about 0.10% of Coya Therapeutics worth $9,434,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares during the period. Newbridge Financial Services Group Inc. purchased a new stake in shares of Coya Therapeutics during the fourth quarter valued at $401,000. CM Management LLC grew its holdings in shares of Coya Therapeutics by 11.1% in the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after purchasing an additional 15,941 shares during the last quarter. AIGH Capital Management LLC grew its holdings in shares of Coya Therapeutics by 85.0% in the fourth quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock worth $6,883,000 after purchasing an additional 551,725 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Coya Therapeutics in the 4th quarter worth about $59,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $6.05 on Thursday. The firm has a 50-day simple moving average of $6.15 and a 200-day simple moving average of $6.33. Coya Therapeutics, Inc. has a one year low of $4.65 and a one year high of $10.24. The firm has a market cap of $101.10 million, a P/E ratio of -9.30 and a beta of 0.49.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, research analysts predict that Coya Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Analysts Set New Price Targets

COYA has been the topic of a number of research analyst reports. D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Tuesday, April 22nd. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, April 28th.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.